Pharmaceutical Care of patients during and after hospitalisation for Acute Coronary Syndrome

Pharmaceutical Care of patients during and after hospitalisation for Acute Coronary Syndrome - PHAIRPLAY

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00004915

Enrollment

200

Registered

2013-05-10

Start date

2013-05-27

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, i.e. STEMI or NSTE-ACS I21

Interventions

Group 1: Patients of the intervention group receive intersectoral pharmaceutical care: detailled pre-discharge counselling according to a multimodal concept serves as main intervention. Further counse

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: a. patients 18 yrs. of age or older b. acute coronary syndrome as confirmed admission diagnosis, i.e. st-segment elevated myocardial infarction (STEMI), non st-segment elevated myocardial infaction (NSTEMI) or unstable angina pectoris (UA). c. informed consent

Exclusion criteria

Exclusion criteria: a. restricted cognitive abilities, i.e. patients who are not able to care for themselves (patients with neurological/psychiatric disorders, patients receiving care or live in a nursing home) b. patients with terminal renal impairment who receive blood dialysis regularly c. patients under antineoplastic treatment d. patients not capable of sufficient knowledge of German language

Design outcomes

Primary

Measure	Time frame
Patient-reported medication adherence 12 months post-discharge as measured by the German Version of the Morisky Medication Adherence Scale / 8-item Version	—

Secondary

Measure	Time frame
Key secondary endpoint: patient-reported physical functioning as key dimension of health-related quality of life, as measured with the German Version of the Physical Funktioning Scale of the SF-12v2® Health Survey 12 months post-discharge. Further secondary endpoints: A. MACCE incidence: incidence and time up to a possible major adverse cardiac or cerebrovascular event during follow-up, i.e. non-fatal reinfarction, any repeat target lesion revascularisation (TLR), cerebrovascular accident or cardiac death. B. Patient's diesease and drug related knowledge: essential content of the in-patient educative session will be assessed with a short self-designed questionnaire at discharge. C. Patient satisfaction: satisfaction with drug related counselling will also be assessed at discharge unsing the drug information scale of the German Hamburger Fragebogen zum Krankenhausaufenthalt. D. Health-related quality of life in the dimensions Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health as measured by the SF-12v2® Health Survey 12 months post-discharge. E. Categorial interpretation of medication adherence: patient-reported medication adherence 12 months post-discharge will be interpreted according to the adherence categories by Morisky et al.	—

Measure

Time frame

Key secondary endpoint: patient-reported physical functioning as key dimension of health-related quality of life, as measured with the German Version of the Physical Funktioning Scale of the SF-12v2® Health Survey 12 months post-discharge. Further secondary endpoints: A. MACCE incidence: incidence and time up to a possible major adverse cardiac or cerebrovascular event during follow-up, i.e. non-fatal reinfarction, any repeat target lesion revascularisation (TLR), cerebrovascular accident or cardiac death. B. Patient's diesease and drug related knowledge: essential content of the in-patient educative session will be assessed with a short self-designed questionnaire at discharge. C. Patient satisfaction: satisfaction with drug related counselling will also be assessed at discharge unsing the drug information scale of the German Hamburger Fragebogen zum Krankenhausaufenthalt. D. Health-related quality of life in the dimensions Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health as measured by the SF-12v2® Health Survey 12 months post-discharge. E. Categorial interpretation of medication adherence: patient-reported medication adherence 12 months post-discharge will be interpreted according to the adherence categories by Morisky et al.

—

Countries

Germany

Contacts

Public ContactJan Fodor

Medizinische Hochschule Hannover

fodor.jan@mh-hannover.de0151/75005550

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026